ReviewAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Nanomaterials for Allergy Diagnosis and Treatment: Advances, Opportunities and Translational Challenges.
Review in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Allergic disorders, including food allergy, asthma, and atopic dermatitis, affect an estimated 10-30% of the global population, with prevalence continuing to rise in industrialized countries. Allergy is driven by dysregulated type 2 T-helper cells (Th2) and immunoglobulin E (IgE) antibody responses. A range of diagnostic tools is available, but most methods are limited by variable sensitivity and specificity, and the inability to predict clinical reactivity. Although allergen-specific immunotherapy (AIT) remains the only etiological therapeutic method for allergic disorders, conventional AITs are limited by frequent administration, risk of adverse events, suboptimal patient adherence, and inconsistent long-term efficacy. Advances in nanotechnology offer emerging opportunities for improving allergy diagnosis and treatment through enhanced analytical sensitivity, targeted allergen delivery and controlled immune modulation. This review provides a comprehensive overview of the latest research on nanomaterials, including their application in nanomaterials-based diagnostic systems and nano-enabled immunotherapies. We highlight their roles in improving allergen-specific IgE detection, refining functional cellular assays, and enabling next-generation immunotherapies through controlled allergen delivery and immunomodulation. We also critically examine key translational barriers and outline essential future directions required for translating nanotechnologies into clinical practice in allergy medicine.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.